Nanobiotix Secures €10M in Non-Dilutive Financing


PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--NANOBIOTIX (Paris:NANO), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that it has received financing approval from HSBC and Bpifrance for a total of €10 million in the form of state-guaranteed loans (Prêts Garantis par l’Etat, or PGE in France).

Each individual lender will provide a loan of €5 million with fixed interest rates of 0.25% and 1.75% per annum. The French government will guarantee 90% of the amounts due.

Each loan has an initial term of 1 year. Repayment of the principal amount due may be further deferred at the option of the Company until June 2025.

The approved loans are non-dilutive to shareholders and will allow the company to extend cash visibility into the third quarter of 2021.


Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotix’s first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s headquarters are in Paris, France, with a US affiliate in Cambridge, MA, and European affiliates in France, Spain and Germany

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.